The theranostic solution for the benefit of patient living with cancer
Radiotherapy combined or not with chemotherapy and surgery is one of the principal therapeutic treatments against cancer. Nearly 2/3 of cancer patients will receive radiation therapy during their treatment. One of the main challenges of radiotherapy is to deliver a sufficient dose in the tumor while sparing the surroundings healthy tissues.
The solution proposed by NH TherAguix is based on nanomedicine: AGuIX® nanoparticles that enhance locally the effect of radiotherapy. This technology is supported by 4 patents and about 50 scientific publications. The nanoparticles are injected in patients and concentrate passively in tumors. Tumors are then finely delineated by magnetic resonance imaging due to the magnetic properties of the AGuIX®. In addition to the precise localization of the tumor, MRI allows to determine the best moment for irradiation. In combination with clinical irradiation, AGuIX® nanoparticles will locally enhanced the radiobiological damages due the radiotherapy. This technology will allow to treat radioresistant cancer and to decrease the secondary effects of radiotherapy by decreasing the dose in healthy tissue.
AGuIX® nanoparticles pave the way for personalized medicine. Thanks to the imaging properties of AGuIX®, only the patients that are likely to present a positive answer to the treatment are selected. The therapeutic protocol is planned for each patient depending of the imaging results.
After a successful completion of toxicity and stability tests, AGuIX® has been produced in cGMP conditions and 1000 vials are available for clinical trials. The first in man injection was successfully performed at Grenoble hospital in July 2016 and five patients have been engaged already.